Myriad Genetics Inc (MYGN) — SEC Filings
Myriad Genetics Inc (MYGN) — 43 SEC filings. Latest: 10-Q (May 6, 2026). Includes 21 8-K, 8 SC 13G/A, 7 10-Q.
View Myriad Genetics Inc on SEC EDGAR
Overview
Myriad Genetics Inc (MYGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: MYRIAD GENETICS INC (MYGN) reported a significant net loss of $358.0 million for the nine months ended September 30, 2025, a substantial increase from the $84.8 million loss in the prior year period. This was primarily driven by a goodwill impairment charge of $234.7 million, with $91.2 million attr
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 3 bearish, 38 neutral, 2 mixed. The dominant filing sentiment for Myriad Genetics Inc is neutral.
Filing Type Overview
Myriad Genetics Inc (MYGN) has filed 7 10-Q, 21 8-K, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of MYGN's 31 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | 614.7M |
| Net Income | -358.0M |
| EPS | -3.88 |
| Debt-to-Equity | 0.32 |
| Cash Position | 145.4M |
| Operating Margin | -62.1% |
| Total Assets | 728.1M |
| Total Debt | 119.5M |
Key Executives
- Paul J. Diaz
Industry Context
Myriad Genetics operates in the highly competitive and rapidly evolving molecular diagnostics and precision medicine industry. Key trends include the increasing demand for genetic testing for disease risk assessment, companion diagnostics, and pharmacogenomics. However, the industry faces challenges related to reimbursement policies, regulatory hurdles, and the need for continuous innovation to stay ahead of technological advancements and competitor offerings.
Top Tags
financials (6) · institutional-ownership (5) · 10-Q (4) · financial-condition (4) · results-of-operations (4) · executive-compensation (3) · corporate-governance (3) · filing (3) · Myriad Genetics (3) · amendment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $358.0M | for the nine months ended September 30, 2025, up from $84.8M in 2024 |
| Goodwill Impairment Charge | $234.7M | recognized during the nine months ended September 30, 2025 |
| Total Revenue | $614.7M | for the nine months ended September 30, 2025, down from $627.0M in 2024 |
| Long-term Debt | $119.5M | as of September 30, 2025, up from $39.6M at December 31, 2024 |
| Cash and Cash Equivalents | $145.4M | as of September 30, 2025, up from $102.4M at December 31, 2024 |
| Net Loss Per Share (Basic and Diluted) | $0.29 | for the three months ended September 30, 2025, up from $0.24 in 2024 |
| Shares Outstanding | 93.2M | as of October 31, 2025 |
| Q2 2025 Revenue | $180.5M | Up 6.05% from $170.2M in Q2 2024, indicating revenue growth. |
| Q2 2025 Net Loss | -$10.1M | Improved from -$20.3M in Q2 2024, showing a 50% reduction in net loss. |
| H1 2025 Revenue | $355.8M | Up 6.18% from $335.1M in H1 2024, demonstrating consistent top-line growth. |
| H1 2025 Net Loss | -$25.2M | Improved from -$40.5M in H1 2024, indicating progress towards profitability. |
| Q2 Revenue Growth | 6.05% | Year-over-year increase in total revenue for the second quarter. |
| H1 Revenue Growth | 6.18% | Year-over-year increase in total revenue for the first half. |
| Q2 2025 U.S. Hereditary Cancer Testing Revenue | $105.2M | A significant component of total revenue, highlighting a key business segment. |
| Period End Date | 20250331 | The report covers financial data up to this date. |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, passive stake in Myriad Genetics for the foreseeable future.","entity":"The Vanguard Group","targetDate":"December 2024","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Myriad Genetics Inc (MYGN)?
Myriad Genetics Inc has 43 recent SEC filings from Jan 2024 to May 2026, including 21 8-K, 8 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MYGN filings?
Across 43 filings, the sentiment breakdown is: 3 bearish, 38 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Myriad Genetics Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Myriad Genetics Inc (MYGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Myriad Genetics Inc?
Key financial highlights from Myriad Genetics Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MYGN?
The investment thesis for MYGN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Myriad Genetics Inc?
Key executives identified across Myriad Genetics Inc's filings include Paul J. Diaz.
What are the main risk factors for Myriad Genetics Inc stock?
Of MYGN's 31 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Myriad Genetics Inc?
Recent forward-looking statements from Myriad Genetics Inc include guidance on {"claim":"Vanguard will maintain a significant, passive stake in Myriad Genetics for the foreseeable future.","entity":".